MSH2 and lung adenocarcinoma: Combining these four cohorts, we revealed that MSH2 expression was the most robust feature associated with increased TMB and smoking signature in multivariate analysis and might be developed as a potential surrogate biomarker of TMB for identifying ICB responders in lung adenocarcinoma (LUAD), one of the commonest types of NSCLC (20, 21).